Advertisement

Autoimmune diseases of muscle

  • R. Hohlfeld
  • A. G. Engel
Part of the Immunology and Medicine Series book series (IMME, volume 24)

Abstract

This chapter focuses primarily on the immunopathogenesis, clinical features and treatment of polymyositis (PM), inclusion body myositis (IBM) and dermatomyositis (DM), the commonly encountered inflammatory myopathies. Parasitic, bacterial, spirochaetal and viral infectious myopathies are not discussed. For recent general reviews, the reader may wish to refer to references 1–5.

Keywords

Interstitial Lung Disease Spinal Muscular Atrophy Neuromuscular Disease Inflammatory Myopathy Membrane Attack Complex 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Engel AG, Hohlfeld R, Banker BQ. The polymyositis and dermatomyositis syndromes. In: Engel AG, Franzini-Armstrong C, editors. Myology, 2nd Edn. New York: McGraw-Hill; 1994:1335–83.Google Scholar
  2. 2.
    Dalakas MC. Polymyositis, dermatomyositis, and inclusion body myositis. N Engl J Med. 1991;325:1487–98.PubMedCrossRefGoogle Scholar
  3. 3.
    Dalakas MC. Inflammatory and toxic myopathies. Curr Opin Neurol Neurosurg. 1992;5:645–54.PubMedGoogle Scholar
  4. 4.
    Engel AG. Inflammatory myopathies. In: Wyngaarden JB, Smith LH, Bennett JC, editors. Cecil Textbook of Medicine. Philadelphia: Saunders, 1992:2256–8.Google Scholar
  5. 5.
    Hohlfeld R, Engel AG. Immune responses in muscle. Semin Neurosci. 1992;4:249–55.CrossRefGoogle Scholar
  6. 6.
    Banker BQ, Victor M. Dermatomyositis (systemic angiopathy) of childhood. Medicine. 1966;45:261–89.PubMedCrossRefGoogle Scholar
  7. 7.
    Banker BQ. Dermatomyositis of childhood. Ultrastructural alterations of muscle and intramuscular blood vessels. J Neuropathol. Exp Neurol. 1975;34:46–75.PubMedCrossRefGoogle Scholar
  8. 8.
    Carpenter S, Karpati G, Rothman S, Watters G. The childhood type of dermatomyositis. Neurology. 1976;26:952–62.PubMedCrossRefGoogle Scholar
  9. 9.
    Jerusalem F, Rakusa M, Engel AG, MacDonald RD. Morphometric analysis of skeletal muscle capillary ultrastructure in inflammatory myopathies. J Neurol Sci. 1974;23:391–401.PubMedCrossRefGoogle Scholar
  10. 10.
    Whitaker JN, Engel WK. Vascular deposits of immunoglobulin and complement in idiopathic inflammatory myopathy. N Engl J Med. 1972;286:333–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Kissel JT, Mendell JR, Rammohan KW. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med. 1986;314:331–4.CrossRefGoogle Scholar
  12. 12.
    Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I. Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibres invaded by T cells. Ann Neurol. 1984;16:193–208.PubMedCrossRefGoogle Scholar
  13. 13.
    De Visser M, Emslie-Smith AM, Engel AG. Early ultrastructural changes in adult dermatomyositis. Capillary abnormalities precede other structural changes in muscle. J Neurol Sci. 1989;94:181–92.PubMedCrossRefGoogle Scholar
  14. 14.
    Emslie-Smith A, Engel AG. Microvascular changes in early and advanced dermatomyositis. A quantitative study. Ann Neurol. 1990;27:343–56.PubMedCrossRefGoogle Scholar
  15. 15.
    Cervera R, Ramirez G, Fernandez-Sola J, et al. Antibodies to endothelial cells in dermatomyositis: association with interstitial lung disease. Br Med J. 1991;302:880–1.CrossRefGoogle Scholar
  16. 16.
    Engel AG, Arahata K. Monoclonal antibody analysis of mononuclear cells in myopathies. II. Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol. 1984;16:209–16.PubMedCrossRefGoogle Scholar
  17. 17.
    Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. III. Immunoelectron microscopy aspects of cell-mediated muscle fiber injury. Ann Neurol. 1986;19:112–25.PubMedCrossRefGoogle Scholar
  18. 18.
    Engel AG, Arahata K. Mononuclear cells in myopathies. Quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. Hum Pathol. 1986;17:704–21.PubMedCrossRefGoogle Scholar
  19. 19.
    Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. IV. Cell-mediated cytotoxicity and muscle fibre necrosis. Ann Neurol. 1988;23:168–73.PubMedCrossRefGoogle Scholar
  20. 20.
    Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. V. Identification and quantification of T8+ cytotoxic and T8+ suppressor cells. Ann Neurol. 1988;23:493–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Engel AG, Arahata K, Emslie-Smith AM Immune effector mechanisms in inflammatory myopathies. Res Pub Assoc Res Nerv Ment Dis. 1990;68:141–57.Google Scholar
  22. 22.
    Phillips JH, Lanier LL. Lectin-dependent and anti-CD3 induced cytotoxicity are preferentially mediated by peripheral blood cytotoxic T lymphocytes expressing Leu7 antigen. J Immunol. 1986;136:1579–85.PubMedGoogle Scholar
  23. 23.
    Rüthlein JH, James SP, Strober W. Role of CD2 in activation and cytotoxic function of CD8/Leu7-positive T cells. J Immunol. 1988;141:3791–7.PubMedGoogle Scholar
  24. 24.
    Marguerie C, Lunardi C, So A. PCR-based analysis of the TCR repertoire in human autoimmune diseases. Immunol Today. 1992;13:336–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Mantegazza R, Andreetta F, Bernasconi P, Baggi F, Oksenberg JR, Simoncini O, Mora M, Cornelio F, Steinman L. Analysis of T cell receptor repertoire of muscle-infiltrating T lymphocytes in polymyositis: Restricted Vα/β rearrangements may indicate antigen-driven selection. J Clin Invest. 1993;91:2880–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Hohlfeld R. Neurological autoimmune disease and the trimolecular complex of T-lymphocytes. Ann Neurol. 1989;25:531–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Karpati G, Pouliot Y, Carpenter S. Expression of immunoreactive major histocompatibility complex products in human skeletal muscles. Ann Neurol. 1988;23:64–72.PubMedCrossRefGoogle Scholar
  28. 28.
    Emslie-Smith AM, Arahata K, Engel AG. Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol. 1989;20:224–31.PubMedCrossRefGoogle Scholar
  29. 29.
    Braciale TJ. Antigen processing for presentation by MHC class I molecules. Curr Opin Immunol. 1992;4:59–62.PubMedCrossRefGoogle Scholar
  30. 30.
    Jardetzky TS, Lane WS, Robinson RA, Madden DR, Wiley DC. Identification of self peptides bound to purified HLA-B27. Nature. 1991;353:326–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Leff RL, Love SJ, Miller FW, et al. Viruses in idiopathic inflammatory myopathies: Absence of candidate viral genomes in muscle. Lancet. 1992;339:1192–5.PubMedCrossRefGoogle Scholar
  32. 32.
    Hohlfeld R, Engel AG, Kunio I, Harper MC. Polymyositis mediated by T lymphocytes that express the γ/δ receptor. N Engl J Med. 1991;13:877–81.CrossRefGoogle Scholar
  33. 33.
    Pluschke G, Rüegg D, Hohlfeld R, Engel AG. Autoaggressive myocytotoxic T-lymphocytes expressing an unusual γ/δ T-cell receptor. J Exp Med. 1992;176:1785–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Hohlfeld R, Engel AG. Expression of 65-kd heat shock proteins in the inflammatory myopathies. Ann Neurol. 1992;32:821–3.PubMedCrossRefGoogle Scholar
  35. 35.
    Blau HM, Webster C. Isolation and characterization of human muscle cells. Proc Natl Acad Sci USA. 1981;78:6523–7.CrossRefGoogle Scholar
  36. 36.
    Hohlfeld R, Engel AG. Induction of HLA-DR expression on human myoblasts with interferon-γ. Am J Pathol. 1990;136:503–8.PubMedGoogle Scholar
  37. 37.
    Hohlfeld R, Engel AG. Coculture with autologous myotubes of cytotoxic T cells isolated from muscle in inflammatory myopathies. Ann Neurol. 1991;29:498–507.PubMedCrossRefGoogle Scholar
  38. 38.
    Schubert W, Zimmermann K, Cramer M, Starzinsky-Powitz A. Lymphocyte antigen Leu-19 as a marker of regeneration in human skeletal muscle. Proc Natl Acad Sci USA. 1989;86:307–11.PubMedCrossRefGoogle Scholar
  39. 39.
    Illa I, Leon-Monzon M, Dalakas MC. Regenerating and denervated human muscle fibers and satellite cells express neural cell adhesion molecules recognized by monoclonal antibodies to natural killer cells. Ann Neurol. 1992;31:46–52.PubMedCrossRefGoogle Scholar
  40. 40.
    Goebels N, Michaelis D, Wekerle H, Hohlfeld R. Human myoblasts as antigen presenting cells. J Immunol. 1992;149:661–7.PubMedGoogle Scholar
  41. 41.
    Bao S, King NJC, Dosremedios CG. Elevated MHC class-I and class-II antigens in cultured human embryonic myoblasts following stimulation with γ-interferon. Immunol Cell Biol. 1990;68:235–42.PubMedCrossRefGoogle Scholar
  42. 42.
    Mantegazza R, Hughes SM, Mitchell D, Travis M, Blau HM, Steinman L. Modulation of MHC class II antigen expression in human myoblasts after treatment with IFN-γ. Neurology. 1991;41:1128–32.PubMedCrossRefGoogle Scholar
  43. 43.
    Roy R, Dansereau G, Tremblay JP, et al. Expression of major histocompatibility complex antigens on human myoblasts. Transplant Proc. 1991;23:799–801.PubMedGoogle Scholar
  44. 44.
    Beauchamp JR, Abraham DJ, Bou-Gharios G, Partridge TA, Olsen I. Expression and function of heterotypic adhesion molecules during differentiation of human skeletal muscle in culture. Am J Pathol. 1992;140:387–401.PubMedGoogle Scholar
  45. 45.
    Cifuentes-Diaz C, Delaporte C, Datreaux B, Charron D, Fardeau M. Class II MHC antigens in normal skeletal muscle. Muscle Nerve. 1992;15:295–302.PubMedCrossRefGoogle Scholar
  46. 46.
    Kalovidouris AE. The role of cytokines in polymyositis: Interferon-γ induces class II and enhances class I major histocompatibility complex antigen expression on cultured human muscle cells. J Lab Clin Med. 1992;120:244–51.PubMedGoogle Scholar
  47. 47.
    Hardiman O, Faustman D, Li X, Sklar RM, Brown RH. Expression of major histocompatibility complex antigens in cultures of clonally derived human myoblasts. Neurology. 1993;43:604–8.PubMedCrossRefGoogle Scholar
  48. 48.
    Springer TA. Adhesion receptors of the immune system. Nature. 1990;346:425–34.PubMedCrossRefGoogle Scholar
  49. 49.
    Jäättelä M. Biologic activities and mechanisms of action of tumor necrosis factor-α/cachectin. Lab Invest. 1991;64:724–42.Google Scholar
  50. 50.
    Nathan C, Yoshida R. Cytokines: interferon-γ. In: Gallin JI, Goldstein IM, Snyderman R, editors. Inflammation: Basic Principles and Clinical Correlates. New York: Raven Press, 1988:229–51.Google Scholar
  51. 51.
    Michaelis D, Goebels N, Hohlfeld R. Constitutive and cytokine-induced expression of HLA and cell adhesion molecules by human myotubes. Am J Pathol. 1993;143:1142–9.PubMedGoogle Scholar
  52. 52.
    Hohlfeld R, Engel AG. Lysis of myotubes by alloreactive cytotoxic T cells and natural killer cells. Relevance to myoblast transplantation. J Clin Invest. 1990;86:370–4.PubMedCrossRefGoogle Scholar
  53. 53.
    Karpati G. The principles and practice of myoblast transfer. In Griggs R, Kaspar G, editors. Myoblast Transfer Therapy. New York: Plenum Press, 1990.Google Scholar
  54. 54.
    Karpati G, Ajdukovic D, Arnold D, et al. Myoblast transfer in Duchenne muscular dystrophy. Ann Neurol. 1993;34:8–17.PubMedCrossRefGoogle Scholar
  55. 55.
    Engel AG. Gene therapy for Duchenne dystrophy. Ann Neurol. 1993;34:3–4.PubMedCrossRefGoogle Scholar
  56. 56.
    Wekerle H, Linington C, Lassmann H, Meyermann R Cellular immune reactivity within the CNS. Trends Neurosci. 1986;9:271–7.CrossRefGoogle Scholar
  57. 57.
    Unanue ER, Allen PM. The basis for the immunoregulatory role of macrophages and other accessory cells. Science. 1987;236:551–8.PubMedCrossRefGoogle Scholar
  58. 58.
    Poher JS. Cytokine-mediated activation of vascular endothelium. Am J Pathol. 1988;133:426–33.Google Scholar
  59. 59.
    Berzofsky JA, Brett SJ, Streicher HZ, Takahashi H. Antigen processing for presentation to T lymphocytes: function, mechanisms and implications for the T cell response. Immunol Rev. 1989;l06:5–3l.Google Scholar
  60. 60.
    Weaver CT, Unanue ER. The costimulatory function of antigen-presenting cells. Immunol Today. 1990;11:49–55.PubMedCrossRefGoogle Scholar
  61. 61.
    Braciale TJ, Braciale VL. Antigen presentation: structural themes and functional variations. Immunol Today. 1991;12:124–9.PubMedCrossRefGoogle Scholar
  62. 62.
    Brodsky FM, Guagliardi L. The cell biology of antigen processing and presentation. Ann Rev Immunol. 1991;9:707–44.CrossRefGoogle Scholar
  63. 63.
    Higuchi I, Montmayor E, Izumo S, Inose M, Osame M. Immunohistochemical characteristics of polymyositis in patients with HTLVI-associated myelopathy and HTLVI carriers. Muscle Nerve. 1993;16:472–6.PubMedCrossRefGoogle Scholar
  64. 64.
    Robinson LR. AAEM case report #22: polymyositis. Muscle Nerve. 1991;14:310–15.PubMedCrossRefGoogle Scholar
  65. 65.
    Illa I, Nath A, Dalakas MC. Immunocytochemical and virological characteristics of HIV-associated inflammatory myopathies: similarities with seronegative polymyositis. Ann Neurol. 1991;29:474–81.PubMedCrossRefGoogle Scholar
  66. 66.
    Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffin JL. Mitochondria1 myopathy caused by long-term zidovudine therapy. N Engl J Med. 1990;322:1098–105.PubMedCrossRefGoogle Scholar
  67. 67.
    Tazelaar HD, Viggiano RW, Pickersgill J, Colby TV. Interstitial lung disease in polymyositis and dermatomyositis: clinical features and prognosis as correlated with histologic findings. Am Rev Resp Dis. 1990;141:727–33.PubMedCrossRefGoogle Scholar
  68. 68.
    Sigurgeirsson B, Lindelöf B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis - a population-based study. N Engl J Med. 1992;326: 363–7.PubMedCrossRefGoogle Scholar
  69. 69.
    Bernard P, Bonnetblanc JM. Dermatomyositis and malignancy. J Invest Dermatol. 1993;100:128S–132S.PubMedCrossRefGoogle Scholar
  70. 70.
    Lotz BP, Engel AG, Nishino H, Stevens JC, Litchy WJ. Inclusion body myositis. Brain. 1969;112:727–42.CrossRefGoogle Scholar
  71. 71.
    Massa R, Weller B, Karpati G, Shoubridge E, Carpenter S. Familial inclusion body myositis among Kurdish-Iranian Jews. Arch Neurol. 1991;48:519–22.PubMedCrossRefGoogle Scholar
  72. 72.
    Askanas V, Serdaroglu P, Engel WK, Alvarez RB. Immunolocalization of ubiquitin in muscle biopsies of patients with inclusion body myositis and oculopharyngeal muscular dystrophy. Neurosci Lett. 199l;130:73–6.PubMedCrossRefGoogle Scholar
  73. 73.
    Askanas V, Engel WK, Alvarez RB. Light and electron microscopic localization of β-amyloid protein in muscle biopsies of patients with inclusion body myositis. Am J Pathol. 1992;141:31–6.PubMedGoogle Scholar
  74. 74.
    Jann S, Beretta S, Moggio M, Adobbati L, Pellegrini G. High-dose intravenous human immunoglobulin in polymyositis resistant to treatment. J Neurol Neurosurg Psychiatry. 1992;55:60–2.CrossRefGoogle Scholar
  75. 75.
    Miller FW, Leitman SF, Cronin ME, et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med. 1992;326:1380–4.PubMedCrossRefGoogle Scholar
  76. 76.
    Dau PC. Plasma exchange in polymyositis and dermatomyositis. N Engl J Med. 1992;327:1030.PubMedCrossRefGoogle Scholar
  77. 77.
    Al-Janadi M, Smith CD, Karsh J. Cyclophosphamide treatment of interstitial pulmonary fibrosis in polymyositis/dermatomyositis. J Rheumatol. 1989;16:1592–6.PubMedGoogle Scholar
  78. 78.
    Soueidan SA, Dalakas MC. Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology. 1993;43:876–9PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1994

Authors and Affiliations

  • R. Hohlfeld
  • A. G. Engel

There are no affiliations available

Personalised recommendations